ARTICLE | Clinical News
Adynovi regulatory update
April 11, 2016 7:00 AM UTC
Baxalta said Japan approved Adynovate to treat hemophilia A in patients ages >=12. Adynovate is a pegylated form of Baxalta’s Advate recombinant Factor VIII that uses PEGylation technology from Nekta...